AzTrials
AzTrials

LeprosyNCT06683690

TGF β 1 Expression Related Gene Polymorphism

An observational study of Leprosy, run by Aswan University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Leprosy is one of the oldest human infectious diseases. It is a chronic infectious contagious, granulomatous disease caused by intracellular bacillus. Mycobacterium leprae, this chronic granulomatous disease presents symptoms that mainly affected the skin, the nervous system and the reticuloendothelial system, also… Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Leprosy
What is being tested?
Measurement of TGF- β1 in leprosy patients
Type of treatment
Surgery or procedure
How many people
60 participants
Where
1 siteEgypt
Study dates
10 Jul 2024to 10 Jul 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: The study will include (30) leprosy patients and (30) normal control , selected from the outpatient clinic of the Dermatology, Venereology, and Andrology Department, at Aswan University Hospital.

Who may be able to join

  • Patients of both sexes with leprosy.
  • Age above 18 years.
  • patients on multidrug therapy of leprosy.

Who cannot join

  • Patients with other dermatological disease.
  • Patients with leprosy reaction.
  • Pregnancy and lactation.
  • Patients with autoimmune disease.

Trial locations and contacts

1 site in 1 country.

Gehad Adel Abd El-Sabour, M.D contact

+201000415446

gehada022@gmail.com

Egypt1 site, 1 recruiting
  • Aswan Universit Hospital

    Aswān

    Mahmoud Ahmed Ali, M.D, 01002364902, dr.mahmoudali@aswu.edu.eg

    Mohamed Amer Ahmed Abdellatif, M.D, 01060394083, mohammed.abdellatif@aswu.edu.eg

    Recruiting

Other trials in Egypt

About this study

Official title: TGF β 1 Expression Related Gene Polymorphism and Their Association With Clinical Types of Leprosy

Leprosy is one of the oldest human infectious diseases. It is a chronic infectious contagious, granulomatous disease caused by intracellular bacillus.

Mycobacterium leprae, this chronic granulomatous disease presents symptoms that mainly affected the skin, the nervous system and the reticuloendothelial system, also other systems can be affected, such as the upper respiratory tract, bones and joints, eyes and adrenal glands.

TGF- β is a pleiotropic cytokine that employs several functions on different types of cells. The effect of other cytokines may finally modulate the cellular response in the presence of TGF- β, causing a different effect depending on the activation state of the cell involved. In addition, TGF- β promotes the healing of inflamed tissue through the stimulation and regulation of extracellular matrix by fibroblasts, in addition to inducing the proliferation of endothelial cells required for angiogenesis. Thus, TGF- β is able to regulate the expression of other growth factors, increasing their level of activity.

Read the detailed description

The spectrum of clinical and histopathological manifestations reflects the immune response elicited by the microorganism in the host leprosy classified into polar groups:

Lepromatous (LL) and Tuberculoid (TT); and borderline spectrum: Borderline Tuberculoid (BT), Borderline Borderline (BB) and Borderline Lepromatous (BL). This classification, proposed by Ridley and Jopling This classification widely used in clinical, immunological, microbiological, and histopathological aspects. While The World Health Organization classifies leprosy clinically as multibacillary and paucibacillary, according to the number of skin lesions and nerve involvement.

In the tuberculoid form of leprosy (paucibacillary), the individual manifests an intense cell-mediated immune response that prevents proliferation of the bacillus, whereas the cell-mediated immune response is compromised in the lepromatous form (multibacillary) contributing to multiplication of the bacillus. In the intermediate forms,the patients exhibit characteristics that vary between the two types.

Leprosy is measured the first disease to be categorized based on the host's immune response. The clinical symptoms of leprosy vary from one patient to another based on the spectrum of disease but more importantly on the type of host's immune response to the bacteria. Both innate and acquired immune responses have been associated with leprosy, but the disease is typically described by the side of a Th1/Th2 response.

Patients with TT are decided by a relevant T-cell immune response, including interleukin-2 (IL-2), IL-4, IL-6, IL-10, interferon-γ (IFN-γ), tumor necrosis factor (TNF), and IL-17 and lymphotoxin, marked by some neural or cutaneous lesions with a few or no bacilli.

Infected macrophages are activated by IFN- γ and clonal expansion of T cells is induced by IL-2 which, in turn, leads to an increase in IFN- γ production. Tumor necrosis factor alpha (TNF- α) also plays a role in the Th1 response. This cytokine contributes to the maintenance of this pattern and acts in synchronism with IFN- γ in the activation of infected macrphages, developing a significant mechanism for the maintenance of the cell-mediated immune response.

In contrast, patients with LL show a superior humoral immune response, characterized by multiple lesions, elevated bacterial load, and reduced lymphocyte production develop a Th2 immune response characterized by intense production of transforming growth factor beta (TGF- β), IL-4, IL-5 and IL-10.

These cytokines induce an incompetent immune response characterized by the high production of antibodies that apply no protective effect against the bacterium.

IL-4 exerts an immunosuppressive effect that leads to an increase in bacterial proliferation and inhibits the proliferation of T cells and monocytes, the expression of CD14 on monocytes and the production of TNF- α, in addition to blocking the synthesis of nitric oxide which is essential for the destruction of intracellular microorganisms. In the 21st century, studies using modern genetic methods such as candidate gene association studies (CGASs) and genome wide association studies (GWASs) have gradually confirmed that the host genetic background play important role in the development of leprosy, and many leprosyassociated variants or genes have been reported. Most leprosy-associated genes are immune related, which is consistent with the finding that leprosy is caused by infection with pathogen.

TGF β1 plays roles in the suppression of T cell responses, inhibiting both IFN γ and IL-2 expression, and has the ability to inhibit the lytic activity of macrophages by suppressing the production of intermediate oxygen-reactive and nitrogen-reactive factors, leading to the progression of infection. So, the production of TGF β1 by macrophages in LL and BL skin lesions, probably as part of the M. leprae evasion mechanism.

Experimental studies on these pathogenic agents have demonstrated a role of TGF- β1 as a suppressor of macrophages. TGF-β1 production in lepromatous patients, which contributes to the anti-inflammatory situation and bacillary persistence observed

Conditions
Leprosy
Being tested
Measurement of TGF- β1 in leprosy patients
Medical subject headings
Leprosy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Measurement of TGF- β1 in leprosy patientsProcedure or surgery

    Study TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.

Study groups in NCT06683690
Study groupRoleWhat they receive
Group A: Leprosy PatientsAbout 30 patients affected with Leorosy
Receives: Procedure: Measurement of TGF- β1 in leprosy patients
Group B: Healthy PeopleAbout 30 Healthy participants
Receives: Procedure: Measurement of TGF- β1 in leprosy patients

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Detection of serum TGF β1

    Detection of serum TGF β1 in leprosy patients and Correlate them with different clinical types of leprosy by taking Blood Samples will be collected from the patients to detect TGF β1gene by DNA extraction and SNP genotyping - Genomic DNA will be extracted from peripheral blood samples, then the polymorphism of the TGF β1 gene marker will be selected, The Blood Samples will be collected from the patients before and after treatment with multidrug therapy of leprosy to detect the level of TGF β1 concentrations by ELISA.

    Measured: One Year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Nov 2024
  2. Study start10 Jul 2024
  3. Primary completion5 Jul 2025 (estimated)
  4. Study completion10 Jul 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06683690
Sponsor's protocol ID
Gehad Adel Abd El-Sabour
Status last verified
Jul 2024
First submitted
8 Nov 2024
Last updated
12 Nov 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Leprosy, run by Aswan University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Gehad Adel Abd El-Sabour, M.D (+201000415446, gehada022@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Detection of serum TGF β1 (time frame: One Year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in